.png "Ellen Gravallese, MD photo")
Brigham and Women's Hospital, Harvard Medical School
Chestnut Hill, MA, United States
Ellen M. Gravallese, M.D. is the Theodore Bevier Bayles Professor of Medicine at Harvard Medical School and Chief of the Division of Rheumatology, Inflammation, and Immunity at Brigham and Women's Hospital. She served as the 83rd President of the ACR and led the ACR's response to the COVID-19 pandemic. Dr. Gravallese received her undergraduate degree from Harvard College and her M.D. from Columbia University. She completed a combined residency in Internal Medicine and Pathology at Brigham and Women’s Hospital, where she also served as a fellow in Rheumatology.
Dr. Gravallese’s laboratory studies the fundamental mechanisms of inflammation and joint destruction in inflammatory arthritis. Her research has provided an understanding of key pathways by which inflammation impacts bone in the rheumatic diseases and has also identified a role for cytosolic DNA sensors in inflammation and bone.
Dr. Gravallese has served on numerous boards and committees, including the Advisory Council for NIAMS, NIH, the Board of Scientific Directors at NIDCR, NIH, and the Board of Directors of the ACR. She was recently elected to AAP and is the recipient of many awards including the ACR Master Award, the Steven Krane Award from the ASBMR and the international Carol Nachman Prize for research. She lectures nationally and internationally and also serves as Associate Editor for the New England Journal of Medicine.
Friday, October 24, 2025
4:10 PM – 4:30 PM Central Time
Disclosure(s): Beam therapuetics: stock (Ongoing); CRISPR therapeutics: stock (Ongoing); Editas: stock (Ongoing); Elsevier textbook Rheumatology: Royalties (Ongoing); Gingko bioworks: stock (Terminated); Intellia Therapeutics: stock (Terminated); New England Journal of Medicine: Employee (Ongoing); UptoDate: Royalties (Ongoing)
Friday, October 24, 2025
4:30 PM – 4:50 PM Central Time
Disclosure(s): Beam therapuetics: stock (Ongoing); CRISPR therapeutics: stock (Ongoing); Editas: stock (Ongoing); Elsevier textbook Rheumatology: Royalties (Ongoing); Gingko bioworks: stock (Terminated); Intellia Therapeutics: stock (Terminated); New England Journal of Medicine: Employee (Ongoing); UptoDate: Royalties (Ongoing)
Friday, October 24, 2025
4:50 PM – 5:10 PM Central Time
Disclosure(s): Beam therapuetics: stock (Ongoing); CRISPR therapeutics: stock (Ongoing); Editas: stock (Ongoing); Elsevier textbook Rheumatology: Royalties (Ongoing); Gingko bioworks: stock (Terminated); Intellia Therapeutics: stock (Terminated); New England Journal of Medicine: Employee (Ongoing); UptoDate: Royalties (Ongoing)
Friday, October 24, 2025
5:10 PM – 5:30 PM Central Time
Disclosure(s): Beam therapuetics: stock (Ongoing); CRISPR therapeutics: stock (Ongoing); Editas: stock (Ongoing); Elsevier textbook Rheumatology: Royalties (Ongoing); Gingko bioworks: stock (Terminated); Intellia Therapeutics: stock (Terminated); New England Journal of Medicine: Employee (Ongoing); UptoDate: Royalties (Ongoing)
